The reversal effect of RN486 on cancer cells co-overexpressing ABCB1 and ABCG2 may be advantageous in the case of ABCB1 and ABCG2 co-overexpressed cells, given that when cancer cells co-overexpress multiple transporters, the inhibitor of one transporter may be the substrate of other transporters, resulting in weakened reversal effect.[34] Furthermore, no discernible impact was found in cancer cells when incubated with cisplatin, which was not a substrate for either ABCB1 or ABCG2. The gene discussed is ABCB1; the disease is cancer.